Susan Bobulsky Sells 11,000 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Susan Bobulsky sold 11,000 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $18.00, for a total transaction of $198,000.00. Following the sale, the insider directly owned 416,775 shares of the company’s stock, valued at $7,501,950. The trade was a 2.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Susan Bobulsky also recently made the following trade(s):

• On Wednesday, March 11th, Susan Bobulsky sold 41,338 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.17, for a total transaction of $544,421.46.

Adaptive Biotechnologies Stock Up 4.0%

Shares of ADPT opened at $17.36 on Wednesday. The stock has a market capitalization of $2.78 billion, a P/E ratio of -52.61 and a beta of 2.15. The firm has a fifty day simple moving average of $14.32 and a two-hundred day simple moving average of $15.66. Adaptive Biotechnologies Corporation has a twelve month low of $9.90 and a twelve month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.03. The business had revenue of $70.87 million during the quarter, compared to analysts’ expectations of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. The firm’s revenue for the quarter was up 35.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.20) EPS. Sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current fiscal year.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors and hedge funds have recently modified their holdings of ADPT. AQR Capital Management LLC lifted its position in shares of Adaptive Biotechnologies by 45.8% in the 1st quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after purchasing an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after purchasing an additional 2,914 shares during the period. Caxton Associates LLP purchased a new stake in shares of Adaptive Biotechnologies in the 1st quarter worth about $93,000. New York State Common Retirement Fund lifted its position in shares of Adaptive Biotechnologies by 39.2% in the 2nd quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after purchasing an additional 13,300 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of Adaptive Biotechnologies by 728.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock worth $4,417,000 after purchasing an additional 333,379 shares during the period. 99.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ADPT. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Wall Street Zen cut shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Morgan Stanley dropped their price target on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. BTIG Research restated a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Finally, Guggenheim reaffirmed a “buy” rating and issued a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Wednesday, May 6th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.57.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.